Prostate Cancer Therapeutics Comprehensive Study by Therapy (Hormone Therapy (Luteizing Hormone - Releasing Hormone Analogs, Luteinizing Hormone - Releasing Hormone Antagonists, and Anti-androgens), Chemotherapy (Systemic Therapy and Regional Chemotherapy), Biologic Therapy, Targeted Therapy), Distribution Channels (Hospital Pharmacy, Retail Pharmacy, Online sales, Others)

Report Objectives / Segmentation Covered

• Hormone Therapy (Luteizing Hormone - Releasing Hormone Analogs, Luteinizing Hormone - Releasing Hormone Antagonists, and Anti-androgens)
• Chemotherapy (Systemic Therapy and Regional Chemotherapy)
• Biologic Therapy
• Targeted Therapy

• Hospital Pharmacy
• Retail Pharmacy
• Online sales
• Others

• 1. Market Overview
  • 1.1. Introduction
  • 1.2. Scope/Objective of the Study
    • 1.2.1. Research Objective
• 2. Executive Summary
  • 2.1. Introduction
• 3. Market Factor Analysis
  • 3.1. Porters Five Forces
  • 3.2. Supply/Value Chain
  • 3.3. PESTEL analysis
  • 3.4. Market Entropy
  • 3.5. Patent/Trademark Analysis
• 4. Global Prostate Cancer Therapeutics, by Therapy and Distribution Channels (value) (2013-2018)
  • 4.1. Introduction
  • 4.2. Global Prostate Cancer Therapeutics (Value)
    • 4.2.1. Global Prostate Cancer Therapeutics by: Therapy (Value)
      • 4.2.1.1. Hormone Therapy (Luteizing Hormone - Releasing Hormone Analogs, Luteinizing Hormone - Releasing Hormone Antagonists, and Anti-androgens)
      • 4.2.1.2. Chemotherapy (Systemic Therapy and Regional Chemotherapy)
      • 4.2.1.3. Biologic Therapy
      • 4.2.1.4. Targeted Therapy
    • 4.2.2. Global Prostate Cancer Therapeutics by: Distribution Channels (Value)
      • 4.2.2.1. Hospital Pharmacy
      • 4.2.2.2. Retail Pharmacy
      • 4.2.2.3. Online sales
      • 4.2.2.4. Others
• 5. Prostate Cancer Therapeutics: Manufacturers/Players Analysis
  • 5.1. Competitive Landscape
    • 5.1.1. Market Share Analysis
      • 5.1.1.1. Top 3
      • 5.1.1.2. Top 5
  • 5.2. Peer Group Analysis (2018)
  • 5.3. BCG Matrix
  • 5.4. Company Profile
    • 5.4.1. AstraZeneca [United Kingdom]
      • 5.4.1.1. Business Overview
      • 5.4.1.2. Products/Services Offerings
      • 5.4.1.3. Financial Analysis
      • 5.4.1.4. SWOT Analysis
    • 5.4.2. Sanofi-Aventis [France]
      • 5.4.2.1. Business Overview
      • 5.4.2.2. Products/Services Offerings
      • 5.4.2.3. Financial Analysis
      • 5.4.2.4. SWOT Analysis
    • 5.4.3. Ipsen [France]
      • 5.4.3.1. Business Overview
      • 5.4.3.2. Products/Services Offerings
      • 5.4.3.3. Financial Analysis
      • 5.4.3.4. SWOT Analysis
    • 5.4.4. Tolmar [United States]
      • 5.4.4.1. Business Overview
      • 5.4.4.2. Products/Services Offerings
      • 5.4.4.3. Financial Analysis
      • 5.4.4.4. SWOT Analysis
    • 5.4.5. Abbott [United States]
      • 5.4.5.1. Business Overview
      • 5.4.5.2. Products/Services Offerings
      • 5.4.5.3. Financial Analysis
      • 5.4.5.4. SWOT Analysis
    • 5.4.6. Astellas Pharma [Japan]
      • 5.4.6.1. Business Overview
      • 5.4.6.2. Products/Services Offerings
      • 5.4.6.3. Financial Analysis
      • 5.4.6.4. SWOT Analysis
    • 5.4.7. Indevus [United States]
      • 5.4.7.1. Business Overview
      • 5.4.7.2. Products/Services Offerings
      • 5.4.7.3. Financial Analysis
      • 5.4.7.4. SWOT Analysis
    • 5.4.8. Dendreon [United States]
      • 5.4.8.1. Business Overview
      • 5.4.8.2. Products/Services Offerings
      • 5.4.8.3. Financial Analysis
      • 5.4.8.4. SWOT Analysis
    • 5.4.9. Ferring [Switzerland]
      • 5.4.9.1. Business Overview
      • 5.4.9.2. Products/Services Offerings
      • 5.4.9.3. Financial Analysis
      • 5.4.9.4. SWOT Analysis
    • 5.4.10. Bristol-Myers Squibb [United States]
      • 5.4.10.1. Business Overview
      • 5.4.10.2. Products/Services Offerings
      • 5.4.10.3. Financial Analysis
      • 5.4.10.4. SWOT Analysis
    • 5.4.11. Pfizer [United States]
      • 5.4.11.1. Business Overview
      • 5.4.11.2. Products/Services Offerings
      • 5.4.11.3. Financial Analysis
      • 5.4.11.4. SWOT Analysis
    • 5.4.12. Sanofi [France]
      • 5.4.12.1. Business Overview
      • 5.4.12.2. Products/Services Offerings
      • 5.4.12.3. Financial Analysis
      • 5.4.12.4. SWOT Analysis
    • 5.4.13. Teva [Israel]
      • 5.4.13.1. Business Overview
      • 5.4.13.2. Products/Services Offerings
      • 5.4.13.3. Financial Analysis
      • 5.4.13.4. SWOT Analysis
    • 5.4.14. Takeda [Japan]
      • 5.4.14.1. Business Overview
      • 5.4.14.2. Products/Services Offerings
      • 5.4.14.3. Financial Analysis
      • 5.4.14.4. SWOT Analysis
    • 5.4.15. Johnson & Johnson [United States]
      • 5.4.15.1. Business Overview
      • 5.4.15.2. Products/Services Offerings
      • 5.4.15.3. Financial Analysis
      • 5.4.15.4. SWOT Analysis
• 6. Global Prostate Cancer Therapeutics Sale, by Therapy and Distribution Channels (value) (2019-2024)
  • 6.1. Introduction
  • 6.2. Global Prostate Cancer Therapeutics (Value)
    • 6.2.1. Global Prostate Cancer Therapeutics by: Therapy (Value)
      • 6.2.1.1. Hormone Therapy (Luteizing Hormone - Releasing Hormone Analogs, Luteinizing Hormone - Releasing Hormone Antagonists, and Anti-androgens)
      • 6.2.1.2. Chemotherapy (Systemic Therapy and Regional Chemotherapy)
      • 6.2.1.3. Biologic Therapy
      • 6.2.1.4. Targeted Therapy
    • 6.2.2. Global Prostate Cancer Therapeutics by: Distribution Channels (Value)
      • 6.2.2.1. Hospital Pharmacy
      • 6.2.2.2. Retail Pharmacy
      • 6.2.2.3. Online sales
      • 6.2.2.4. Others
• 7. Appendix
  • 7.1. Acronyms
• 8. Methodology and Data Source
  • 8.1. Methodology/Research Approach
    • 8.1.1. Research Programs/Design
    • 8.1.2. Market Size Estimation
    • 8.1.3. Market Breakdown and Data Triangulation
  • 8.2. Data Source
    • 8.2.1. Secondary Sources
    • 8.2.2. Primary Sources
  • 8.3. Disclaimer

• Table 1. Prostate Cancer Therapeutics: by Therapy(USD Million)
• Table 2. Prostate Cancer Therapeutics: by Distribution Channels(USD Million)
• Table 3. Company Basic Information, Sales Area and Its Competitors
• Table 4. Company Basic Information, Sales Area and Its Competitors
• Table 5. Company Basic Information, Sales Area and Its Competitors
• Table 6. Company Basic Information, Sales Area and Its Competitors
• Table 7. Company Basic Information, Sales Area and Its Competitors
• Table 8. Company Basic Information, Sales Area and Its Competitors
• Table 9. Company Basic Information, Sales Area and Its Competitors
• Table 10. Company Basic Information, Sales Area and Its Competitors
• Table 11. Company Basic Information, Sales Area and Its Competitors
• Table 12. Company Basic Information, Sales Area and Its Competitors
• Table 13. Company Basic Information, Sales Area and Its Competitors
• Table 14. Company Basic Information, Sales Area and Its Competitors
• Table 15. Company Basic Information, Sales Area and Its Competitors
• Table 16. Company Basic Information, Sales Area and Its Competitors
• Table 17. Company Basic Information, Sales Area and Its Competitors
• Table 18. Prostate Cancer Therapeutics: by Therapy(USD Million)
• Table 19. Prostate Cancer Therapeutics: by Distribution Channels(USD Million)
• Table 20. Research Programs/Design for This Report
• Table 21. Key Data Information from Secondary Sources
• Table 22. Key Data Information from Primary Sources

• Figure 1. Porters Five Forces
• Figure 2. Supply/Value Chain
• Figure 3. PESTEL analysis
• Figure 4. Global Prostate Cancer Therapeutics: by Therapy USD Million (2013-2018)
• Figure 5. Global Prostate Cancer Therapeutics: by Distribution Channels USD Million (2013-2018)
• Figure 6. Global Prostate Cancer Therapeutics share by Players 2018 (%)
• Figure 7. Global Prostate Cancer Therapeutics share by Players (Top 3) 2018(%)
• Figure 8. Global Prostate Cancer Therapeutics share by Players (Top 5) 2018(%)
• Figure 9. BCG Matrix for key Companies
• Figure 10. AstraZeneca [United Kingdom] Revenue, Net Income and Gross profit
• Figure 11. AstraZeneca [United Kingdom] Revenue: by Geography 2018
• Figure 12. Sanofi-Aventis [France] Revenue, Net Income and Gross profit
• Figure 13. Sanofi-Aventis [France] Revenue: by Geography 2018
• Figure 14. Ipsen [France] Revenue, Net Income and Gross profit
• Figure 15. Ipsen [France] Revenue: by Geography 2018
• Figure 16. Tolmar [United States] Revenue, Net Income and Gross profit
• Figure 17. Tolmar [United States] Revenue: by Geography 2018
• Figure 18. Abbott [United States] Revenue, Net Income and Gross profit
• Figure 19. Abbott [United States] Revenue: by Geography 2018
• Figure 20. Astellas Pharma [Japan] Revenue, Net Income and Gross profit
• Figure 21. Astellas Pharma [Japan] Revenue: by Geography 2018
• Figure 22. Indevus [United States] Revenue, Net Income and Gross profit
• Figure 23. Indevus [United States] Revenue: by Geography 2018
• Figure 24. Dendreon [United States] Revenue, Net Income and Gross profit
• Figure 25. Dendreon [United States] Revenue: by Geography 2018
• Figure 26. Ferring [Switzerland] Revenue, Net Income and Gross profit
• Figure 27. Ferring [Switzerland] Revenue: by Geography 2018
• Figure 28. Bristol-Myers Squibb [United States] Revenue, Net Income and Gross profit
• Figure 29. Bristol-Myers Squibb [United States] Revenue: by Geography 2018
• Figure 30. Pfizer [United States] Revenue, Net Income and Gross profit
• Figure 31. Pfizer [United States] Revenue: by Geography 2018
• Figure 32. Sanofi [France] Revenue, Net Income and Gross profit
• Figure 33. Sanofi [France] Revenue: by Geography 2018
• Figure 34. Teva [Israel] Revenue, Net Income and Gross profit
• Figure 35. Teva [Israel] Revenue: by Geography 2018
• Figure 36. Takeda [Japan] Revenue, Net Income and Gross profit
• Figure 37. Takeda [Japan] Revenue: by Geography 2018
• Figure 38. Johnson & Johnson [United States] Revenue, Net Income and Gross profit
• Figure 39. Johnson & Johnson [United States] Revenue: by Geography 2018
• Figure 40. Global Prostate Cancer Therapeutics: by Therapy USD Million (2013-2018)
• Figure 41. Global Prostate Cancer Therapeutics: by Distribution Channels USD Million (2013-2018)

• AstraZeneca [United Kingdom]
• Sanofi-Aventis [France]
• Ipsen [France]
• Tolmar [United States]
• Abbott [United States]
• Astellas Pharma [Japan]
• Indevus [United States]
• Dendreon [United States]
• Ferring [Switzerland]
• Bristol-Myers Squibb [United States]
• Pfizer [United States]
• Sanofi [France]
• Teva [Israel]
• Takeda [Japan]
• Johnson & Johnson [United States]